Relevant bibliographies by topics / Abstract Targeted radionuclide therapy (TRT) / Journal articles
To see the other types of publications on this topic, follow the link: Abstract Targeted radionuclide therapy (TRT).

Journal articles on the topic 'Abstract Targeted radionuclide therapy (TRT)'

Author: Grafiati
Published: 6 July 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Abstract Targeted radionuclide therapy (TRT).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Nguyen, Thanh Phuong T., Caroline P. Kerr, Joseph J. Grudzinski, et al. "Abstract 6407: Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors." Cancer Research 83, no. 7_Supplement (2023): 6407. http://dx.doi.org/10.1158/1538-7445.am2023-6407.

Full text
Abstract:
Abstract Background: Targeted radionuclide therapy (TRT) delivers radiation treatment systemically to tumor sites via a therapeutic radionuclide-linked tumor-selective targeting vector. NM600 is an alkylphosphocholine analog selectively taken up and retained in murine and human tumor cells. We previously showed that low dose radiation delivery with 90Y-NM600 improves tumor response to immune checkpoint inhibitors (ICIs). Understanding the effect of different radionuclide physical properties (emission type, linear energy transfer (LET), half-life, and tissue range) on immunomodulation of metast
APA, Harvard, Vancouver, ISO, and other styles
2

Kerr, Caroline P., Joseph J. Grudzinski, Carolina A. Ferreira, et al. "Abstract 2828: Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response." Cancer Research 83, no. 7_Supplement (2023): 2828. http://dx.doi.org/10.1158/1538-7445.am2023-2828.

Full text
Abstract:
Abstract Background: Sequencing of immune checkpoint inhibitors (ICI) and external beam radiation therapy (EBRT) for cancer treatment has been studied, but the optimal sequencing has yet to be determined. While some studies have noted therapeutic advantages of priming the tumor immune microenvironment with EBRT prior to ICI, others have described the benefit of modulating the tumor infiltrating lymphocyte (TIL) population with ICI before EBRT. Targeted radionuclide therapy (TRT) approaches allow investigation of how irradiation by a tumor-targeted radionuclide and differences in emission type,
APA, Harvard, Vancouver, ISO, and other styles
3

Pal, Debjani, Miguel Toro Gonzáleza, Amber N. Bibleb, et al. "Abstract 480: Nanotherapeutic strategies to improve targeted radionuclide therapy." Cancer Research 84, no. 6_Supplement (2024): 480. http://dx.doi.org/10.1158/1538-7445.am2024-480.

Full text
Abstract:
Abstract Cancer is a leading cause of death worldwide. Several multidisciplinary approaches exist for cancer treatment, including radiotherapy and chemotherapy. Radiotherapy uses high-energy radiation to kill cancer cells; chemotherapy inhibits cancer cell proliferation and often kills cells by targeting the cell cycle. Resistance to radiotherapy and chemotherapy is a key determining factor in the outcome of therapeutic efficacy. Conventional nontargeted radiotherapy also affects distant nonirradiated cells, leading to DNA damage and changes in the cell cycle that are often linked to secondary
APA, Harvard, Vancouver, ISO, and other styles
4

Adhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, et al. "Abstract 2732: A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy." Cancer Research 82, no. 12_Supplement (2022): 2732. http://dx.doi.org/10.1158/1538-7445.am2022-2732.

Full text
Abstract:
Abstract Background: Immunotherapy with chimeric antigen receptor - T (CAR-T) cells and targeted radionuclide therapy (TRT) are two highly promising therapies in cancer treatment. Often, these therapies show limited efficacy in complete eradication of cancer cells making the combination of these two therapies an attractive cancer treatment option. The complications involved in dosing and scheduling of these therapies make mathematical modeling an appropriate method for analyzing and predicting disease response to these therapies. Here we propose a mathematical model evaluating disease response
APA, Harvard, Vancouver, ISO, and other styles
5

Kerr, Caroline P., Amber M. Bates, Joseph J. Grudzinski, et al. "Abstract 1306: Radionuclide-specific effects of 90Y-, 177Lu-, or 225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhancing immunotherapy response in murine tumor models." Cancer Research 82, no. 12_Supplement (2022): 1306. http://dx.doi.org/10.1158/1538-7445.am2022-1306.

Full text
Abstract:
Abstract Purpose: In preclinical studies, we have demonstrated that delivering low dose radiation to all tumor sites utilizing 90Y-NM600 improves the response to immune checkpoint inhibitors (ICIs). NM600 is an alkylphosphocholine analog that is selectively taken up and retained in murine and human tumors. In this study, the immunomodulatory capacities of three distinct radionuclides (90Y, 177Lu, 225Ac) were compared using immunologically cold syngeneic murine tumor models: MOC2 head and neck squamous cell carcinoma (HNSCC) and B78 melanoma. We hypothesized that physical properties of radionuc
APA, Harvard, Vancouver, ISO, and other styles
6

Adhikarla, Vikram, Dennis Awuah, Enrico Caserta, et al. "Abstract 7374: Mathematical modeling of targeted radionuclide therapy and CAR-T cell immunotherapy for maximizing therapeutic efficacy in multiple myeloma." Cancer Research 84, no. 6_Supplement (2024): 7374. http://dx.doi.org/10.1158/1538-7445.am2024-7374.

Full text
Abstract:
Abstract Background: Resistance of cancer cells to monotherapies has led to the development of sequential or combination therapy regimens. However, dosing and scheduling of these therapies is challenging due to the numerous dosing and scheduling combinations that can be given. Mathematical models are thus critical tools for addressing this challenge as multiple therapy combinations can be tested in silico to finalize a patient-specific therapeutic regimen in vivo. Here we develop a mathematical framework for combining targeted radiation therapy (TRT) with Chimeric Antigen Receptor (CAR)-T cell
APA, Harvard, Vancouver, ISO, and other styles
7

Ruder, Samuel, Michael Sun, Andres Ricaurte Fajardo, et al. "Abstract 7582: Descriptive analysis of patients with mCRPC and liver metastases receiving alpha and beta PSMA targeted radionuclide therapy (PSMA-TRT)." Cancer Research 84, no. 6_Supplement (2024): 7582. http://dx.doi.org/10.1158/1538-7445.am2024-7582.

Full text
Abstract:
Abstract Introduction: Predictors of outcomes after PSMA-TRT are still being established. Liver metastases (mets) have been associated with poor response. Mutations in genes encoding DNA damage repair (DDR) and TP53 affect radiosensitivity. Here we describe a cohort of patients with mCRPC and liver metastases treated on clinical trials of PSMA-TRT. Methods: 39 patients with liver mets were enrolled on phase I/II PSMA-TRT studies between Jan 2006 to Apr 2022. Patients received alpha therapy (225Ac-J591), beta therapy (fractionated 177Lu-PSMA-617, single-dose and fractionated 177Lu-J591) or a co
APA, Harvard, Vancouver, ISO, and other styles
8

Sheehan-Klenk, Julia, Caroline P. Kerr, Thanh P. Nguyen, et al. "Abstract 6117: Dose, dose rate, and linear energy transfer influence tumor immunologic and DNA damage response following alpha- and beta-emitting radionuclides." Cancer Research 83, no. 7_Supplement (2023): 6117. http://dx.doi.org/10.1158/1538-7445.am2023-6117.

Full text
Abstract:
Abstract Background: The low response rate to immunotherapies in poorly immunogenic cancers highlights the potential for combination therapies that propagate an anti-tumor response in metastatic settings. Targeted radionuclide therapy (TRT) can deliver radiation to metastatic tumor sites. In preclinical studies, combining low dose TRT with immune checkpoint blockade augments the anti-tumor immune response, promoting the immune susceptibility of metastatic disease sites. Radionuclides differ in their physical properties such as emission type, linear energy transfer (LET), half-life, and tissue
APA, Harvard, Vancouver, ISO, and other styles
9

Garcia-Prada, Clara Diaz, Lena Carmes, Ali Parach, et al. "Abstract P009: Gadolinium-based nanoparticles sensitize ovarian peritoneal carcinomatosis to targeted radionuclide therapy." Clinical Cancer Research 31, no. 2_Supplement (2025): P009. https://doi.org/10.1158/1557-3265.targetedtherap-p009.

Full text
Abstract:
Abstract In 2024, around 13,000 women are expected to die from Ovarian Cancer (OC) in the US. Masked disease progression leads to late-stage diagnosis after the disease has spread to the peritoneal cavity (peritoneal carcinomatosis, PC). Treatments do not show substantial curative benefits, as disease will reoccur in 70-90% of patients. Targeted Radionuclide Therapy (TRT) specifically irradiates tumors sparing the surrounding healthy tissues, offering an attractive therapeutic option for metastatic spread. Here, we investigated the radiosensitizing effects of Gadolinium-based nanoparticles (Gd
APA, Harvard, Vancouver, ISO, and other styles
10

Cold, Sigrid, Pragalath Sadasivam, Myrto Ischyropoulou, et al. "Abstract 570: Preclinical insights into 161Tb-trastuzumab and immune checkpoint combination therapy for cancer in a HER2-expressing murine cancer model." Cancer Research 85, no. 8_Supplement_1 (2025): 570. https://doi.org/10.1158/1538-7445.am2025-570.

Full text
Abstract:
Abstract Introduction: Targeted radionuclide therapy (TRT) is a unique treatment option allowing for in vivo imaging and delivery of lethal radiation directly and specifically to solid cancers. As TRT is generally well-tolerated with limited side effects, it holds a significant potential for use in combination with other therapies such as immunotherapy. However, preclinical assessment of this combinational pair has been limited by the lack of relevant animal models. To address this, we established a fully immunocompetent animal model bearing murine tumors expressing a human target making the m
APA, Harvard, Vancouver, ISO, and other styles
11

Vorontsova, M., T. Karmakova, A. Pankratov, and A. Kaprin. "Current Trends in Targeted Radionuclide Therapy Development." Medical Radiology and radiation safety 66, no. 6 (2021): 63–70. http://dx.doi.org/10.12737/1024-6177-2021-66-6-63-70.

Full text
Abstract:
Introduction
 1. Features of Targeted Delivery of Therapeutic Radionuclides
 2. Design of Pharmaceuticals for Targeted Radionuclide Therapy (TRT)
 2.1. Radionuclides
 2.2. Synthesis of Radioconjugates
 2.3. Targeting Carriers 
 4. Subcellular Targeting of Radionuclides
 5. TRT Dosimetry
 Conclusion
APA, Harvard, Vancouver, ISO, and other styles
12

van der Wal, Bart C. H., and Ekaterina Dadachova. "Targeted Radionuclide Therapy of Cancer and Infections." International Journal of Molecular Sciences 24, no. 10 (2023): 9081. http://dx.doi.org/10.3390/ijms24109081.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Metcalf, Julie, Alexander Nielsen, Suma Prabhu, et al. "Abstract LB313: EGFRvIII-targeted alpha therapy shows significant therapeutic efficacy as both a single-agent and in combination with standard of care against preclinical GBM models." Cancer Research 83, no. 8_Supplement (2023): LB313. http://dx.doi.org/10.1158/1538-7445.am2023-lb313.

Full text
Abstract:
Abstract Targeted alpha therapy (TAT) is a rapidly advancing class of radiotherapeutics that can effectively deliver potent and local radiation to cancer cells while sparing the surrounding normal cells. TATs hold great promise for treatment-resistant tumors such as glioblastoma multiforme (GBM) due to the extensive DNA damage and cell death induced by alpha particles. GBM is an aggressive and lethal primary adult brain tumor that is highly resistant to external beam radiation and chemotherapy. Herein, we present the preclinical evaluation of a novel TAT for treatment of GBM targeting the most
APA, Harvard, Vancouver, ISO, and other styles
14

Kerr, Caroline P., Joseph J. Grudzinski, Thanh Phuong Nguyen, Reinier Hernandez, Jamey P. Weichert, and Zachary S. Morris. "Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment." Pharmaceutics 15, no. 1 (2022): 128. http://dx.doi.org/10.3390/pharmaceutics15010128.

Full text
Abstract:
Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of treating all disease sites following intravenous injection and selective tumor uptake and retention—a particularly beneficial property in metastatic disease settings. The therapeutic value of combining radiation therapy with immune checkpoint blockade to treat metastases has been demonstrated in pr
APA, Harvard, Vancouver, ISO, and other styles
15

Tomiyoshi, Katsumi, Lydia J. Wilson, Firas Mourtada, et al. "Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology." Pharmaceutics 16, no. 11 (2024): 1458. http://dx.doi.org/10.3390/pharmaceutics16111458.

Full text
Abstract:
Targeted radionuclide therapy (TRT) for internal pathway-directed treatment is a game changer for precision medicine. TRT improves tumor control while minimizing damage to healthy tissue and extends the survival for patients with cancer. The application of theranostic-paired TRT along with cellular phenotype and genotype correlative analysis has the potential for malignant disease management. Chelation chemistry is essential for the development of theranostic-paired radiopharmaceuticals for TRT. Among image-guided TRT, 68Ga and 99mTc are the current standards for diagnostic radionuclides, whil
APA, Harvard, Vancouver, ISO, and other styles
16

Obata, Honoka, Mikako Ogawa, and Michael R. Zalutsky. "DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy." Pharmaceutics 15, no. 7 (2023): 1926. http://dx.doi.org/10.3390/pharmaceutics15071926.

Full text
Abstract:
The present review aims to explore the potential targets/partners for future targeted radionuclide therapy (TRT) strategies, wherein cancer cells often are not killed effectively, despite receiving a high average tumor radiation dose. Here, we shall discuss the key factors in the cancer genome, especially those related to DNA damage response/repair and maintenance systems for escaping cell death in cancer cells. To overcome the current limitations of TRT effectiveness due to radiation/drug-tolerant cells and tumor heterogeneity, and to make TRT more effective, we propose that a promising strat
APA, Harvard, Vancouver, ISO, and other styles
17

Ferro-Flores, Guillermina, Erika Azorín-Vega, Blanca Ocampo-García, Myrna Luna-Gutiérrez, Pedro Cruz-Nova, and Laura Meléndez-Alafort. "Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose." International Journal of Molecular Sciences 26, no. 14 (2025): 6968. https://doi.org/10.3390/ijms26146968.

Full text
Abstract:
Targeted radionuclide therapy (TRT) utilizes radiopharmaceuticals to deliver radiation directly to cancer cells while sparing healthy tissues. Beyond the absorbed dose of ablative radiation, TRT induces non-targeted effects (NTEs) that significantly enhance its therapeutic efficacy. These effects include radiation-induced bystander effects (RIBEs), abscopal effects (AEs), radiation-induced genomic instability (RIGI), and adaptive responses, which collectively influence the behavior of cancer cells and the tumor microenvironment (TME). TRT also modulates immune responses, promoting immune-media
APA, Harvard, Vancouver, ISO, and other styles
18

Adhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, et al. "A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy." Cancers 13, no. 20 (2021): 5171. http://dx.doi.org/10.3390/cancers13205171.

Full text
Abstract:
Targeted radionuclide therapy (TRT) has recently seen a surge in popularity with the use of radionuclides conjugated to small molecules and antibodies. Similarly, immunotherapy also has shown promising results, an example being chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies. Moreover, TRT and CAR-T therapies possess unique features that require special consideration when determining how to dose as well as the timing and sequence of combination treatments including the distribution of the TRT dose in the body, the decay rate of the radionuclide, and the proliferati
APA, Harvard, Vancouver, ISO, and other styles
19

Li, Mengshi, Edwin A. Sagastume, Dongyoul Lee, et al. "203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer." Current Medicinal Chemistry 27, no. 41 (2020): 7003–31. http://dx.doi.org/10.2174/0929867327999200727190423.

Full text
Abstract:
Receptor-targeted image-guided Radionuclide Therapy (TRT) is increasingly recognized as a promising approach to cancer treatment. In particular, the potential for clinical translation of receptor-targeted alpha-particle therapy is receiving considerable attention as an approach that can improve outcomes for cancer patients. Higher Linear-energy Transfer (LET) of alpha-particles (compared to beta particles) for this purpose results in an increased incidence of double-strand DNA breaks and improved-localized cancer-cell damage. Recent clinical studies provide compelling evidence that alpha-TRT h
APA, Harvard, Vancouver, ISO, and other styles
20

Cheng, Wee Mee, Zanariah Hussien1, and Nor Salita binti Ali. "LOCAL EXPERIENCE WITH TARGETED RADIONUCLIDE THERAPY IN MALIGNANT PHEOCHROMOCYTOMA AND PARAGANGLIOMA." Journal of the ASEAN Federation of Endocrine Societies 39, S1 (2024): 74. https://doi.org/10.15605/jafes.039.s1.124.

Full text
Abstract:
INTRODUCTION/BACKGROUNDTargeted radionuclide therapy (TRT) is a promising therapeutic option for patients with malignant pheochromocytoma and paraganglioma (PPGL) but it is not widely available locally. METHODOLOGYWe conducted a retrospective cohort study of patients with malignant PPGL from 2000 to 2023. RESULTSWe report the experience of TRT among 15 patients with malignant PPGL (26% pheochromocytoma, 60% paraganglioma, 13% combined) under follow-up in a tertiary endocrine referral centre from 2000 to 2023. There was equal gender distribution with a median of 41 years at diagnosis. They had
APA, Harvard, Vancouver, ISO, and other styles
21

Malcolm, Javian, Nadia Falzone, Boon Lee, and Katherine Vallis. "Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response." Cancers 11, no. 2 (2019): 268. http://dx.doi.org/10.3390/cancers11020268.

Full text
Abstract:
Compared to external beam radiotherapy, targeted radionuclide therapy (TRT) allows for systemic radiation treatment of metastatic lesions. Published work on recent strategies to improve patient management and response to TRT through individualising patient treatment, modifying treatment pharmacokinetics and increasing anticancer potency are discussed in this review, with a special focus on the application of clinically evaluated radiolabelled ligands and peptides in the treatment of neuroendocrine and prostate cancers.
APA, Harvard, Vancouver, ISO, and other styles
22

Müller, Cristina, Martin Béhé, Susanne Geistlich, Nicholas P. van der Meulen, and Roger Schibli. "Targeted Radiotherapeutics from 'Bench-to-Bedside'." CHIMIA International Journal for Chemistry 74, no. 12 (2020): 939–45. http://dx.doi.org/10.2533/chimia.2020.939.

Full text
Abstract:
The concept of targeted radionuclide therapy (TRT) is the accurate and efficient delivery of radiation to disseminated cancer lesions while minimizing damage to healthy tissue and organs. Critical aspects for successful development of novel radiopharmaceuticals for TRT are: i) the identification and characterization of suitable targets expressed on cancer cells; ii) the selection of chemical or biological molecules which exhibit high affinity and selectivity for the cancer cell-associated target; iii) the selection of a radionuclide with decay properties that suit the properties of the targeti
APA, Harvard, Vancouver, ISO, and other styles
23

Ruigrok, Eline A. M., Wytske M. van Weerden, Julie Nonnekens, and Marion de Jong. "The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research." Pharmaceutics 11, no. 11 (2019): 560. http://dx.doi.org/10.3390/pharmaceutics11110560.

Full text
Abstract:
Prostate specific membrane antigen (PSMA) has become a major focus point in the research and development of prostate cancer (PCa) imaging and therapeutic strategies using radiolabeled tracers. PSMA has shown to be an excellent target for PCa theranostics because of its high expression on the membrane of PCa cells and the increase in expression during disease progression. Therefore, numerous PSMA-targeting tracers have been developed and (pre)clinically studied with promising results. However, many of these PSMA-targeting tracers show uptake in healthy organs such as the salivary glands, causin
APA, Harvard, Vancouver, ISO, and other styles
24

Patel, Ravi B., Reinier Hernandez, Peter Carlson, et al. "Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade." Science Translational Medicine 13, no. 602 (2021): eabb3631. http://dx.doi.org/10.1126/scitranslmed.abb3631.

Full text
Abstract:
Molecular and cellular effects of radiotherapy on tumor microenvironment (TME) can help prime and propagate antitumor immunity. We hypothesized that delivering radiation to all tumor sites could augment response to immunotherapies. We tested an approach to enhance response to immune checkpoint inhibitors (ICIs) by using targeted radionuclide therapy (TRT) to deliver radiation semiselectively to tumors. NM600, an alkylphosphocholine analog that preferentially accumulates in most tumor types, chelates a radioisotope and semiselectively delivers it to the TME for therapeutic or diagnostic applica
APA, Harvard, Vancouver, ISO, and other styles
25

Spoormans, Kaat, Melissa Crabbé, Lara Struelens, Marijke De Saint-Hubert, and Michel Koole. "A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT)." Pharmaceutics 14, no. 10 (2022): 2007. http://dx.doi.org/10.3390/pharmaceutics14102007.

Full text
Abstract:
Targeted radionuclide therapy (TRT) uses radiopharmaceuticals to specifically irradiate tumor cells while sparing healthy tissue. Response to this treatment highly depends on the absorbed dose. Tumor control probability (TCP) models aim to predict the tumor response based on the absorbed dose by taking into account the different characteristics of TRT. For instance, TRT employs radiation with a high linear energy transfer (LET), which results in an increased effectiveness. Furthermore, a heterogeneous radiopharmaceutical distribution could result in a heterogeneous dose distribution at a tissu
APA, Harvard, Vancouver, ISO, and other styles
26

Sun, M., C. Thomas, J. Stangl-Kremser, et al. "1822P PSMA-alpha targeted radionuclide therapy (TRT) with or without prior PSMA-beta TRT." Annals of Oncology 34 (October 2023): S987. http://dx.doi.org/10.1016/j.annonc.2023.09.2770.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Aprile, Carlo, Onelio Geatti, Letizia Canziani, and Lorenzo Lodola. "Editorial for the Special Issue “Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design”." Current Issues in Molecular Biology 46, no. 3 (2024): 2398–401. http://dx.doi.org/10.3390/cimb46030152.

Full text
Abstract:
Targeted radionuclide therapy (TRT) is gaining wide and rapid acceptance in clinical practice as it can deliver alpha or beta irradiation to a tumor-associated target which may be present in the tumor cell itself or in the microenvironment [...]
APA, Harvard, Vancouver, ISO, and other styles
28

Funeh, Cyprine Neba, Jessica Bridoux, Thomas Ertveldt, et al. "Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy." Pharmaceutics 15, no. 5 (2023): 1378. http://dx.doi.org/10.3390/pharmaceutics15051378.

Full text
Abstract:
The precise delivery of cytotoxic radiation to cancer cells through the combination of a specific targeting vector with a radionuclide for targeted radionuclide therapy (TRT) has proven valuable for cancer care. TRT is increasingly being considered a relevant treatment method in fighting micro-metastases in the case of relapsed and disseminated disease. While antibodies were the first vectors applied in TRT, increasing research data has cited antibody fragments and peptides with superior properties and thus a growing interest in application. As further studies are completed and the need for no
APA, Harvard, Vancouver, ISO, and other styles
29

Delpassand, Ebrahim S., Mohammad Jawed Hashmi, Julia Kazakin, et al. "Abstract CT224: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)." Cancer Research 84, no. 7_Supplement (2024): CT224. http://dx.doi.org/10.1158/1538-7445.am2024-ct224.

Full text
Abstract:
Abstract INTRODUCTION: Targeted α therapy (TAT) in mCRPC is a rapidly advancing class of radiotherapeutics that can effectively deliver potent and local radiation selectively to cancer cells while sparing the surrounding normal cells. Retrospective studies of 225Ac PSMA-RLT (radioligand therapy), have shown promise in pts with mCRPC, where activity correlates with disease characteristics and prior therapies. FPI-2265 (225Ac-PSMA-I&T) consists of a small-molecule PSMA-targeting ligand coupled with a 225Ac radionuclide. Here we present the initial results from TATCIST, an ongoing, open-label
APA, Harvard, Vancouver, ISO, and other styles
30

Potluri, Hemanth, Carolina Ferreira, Joseph Grudzinski, et al. "594 Combination of antigen-specific vaccination and targeted radionuclide therapy improves anti-tumor efficacy in a murine prostate model." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A624. http://dx.doi.org/10.1136/jitc-2021-sitc2021.594.

Full text
Abstract:
BackgroundWhile checkpoint blockade has been unsuccessful in prostate cancer trials, the approval of Sipuleucel-T demonstrates the value of antigen-specific vaccination approaches for this disease. We have studied a DNA vaccine specific for the ligand-binding domain of the androgen receptor (pTVG-AR) as a more scalable vaccination approach, though its efficacy is likely limited by the immunosuppressive prostate microenvironment. External beam radiotherapy has been shown to sensitize poorly responsive tumors to immunotherapy, but is infeasible for patients with widely metastatic disease. Our gr
APA, Harvard, Vancouver, ISO, and other styles
31

Ruigrok, Eline A. M., Nicole S. Verkaik, Erik de Blois, et al. "Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment." International Journal of Molecular Sciences 23, no. 14 (2022): 8037. http://dx.doi.org/10.3390/ijms23148037.

Full text
Abstract:
Prostate specific membrane antigen targeted radionuclide therapy (PSMA-TRT) is a promising novel treatment for prostate cancer (PCa) patients. However, PSMA-TRT cannot be used for curative intent yet, thus additional research on how to improve the therapeutic efficacy is warranted. A potential way of achieving this, is combining TRT with poly ADP-ribosylation inhibitors (PARPi), which has shown promising results for TRT of neuroendocrine tumor cells. Currently, several clinical trials have been initiated for this combination for PCa, however so far, no evidence of synergism is available for PC
APA, Harvard, Vancouver, ISO, and other styles
32

Poppy Filmonov and Ayesh Mahmood. "Targeted Radionuclide Therapy for the Treatment of Metastatic Bone Disease: A Retrospective Analysis in Moscow, Russia." Sriwijaya Journal of Radiology and Imaging Research 2, no. 2 (2024): 104–16. http://dx.doi.org/10.59345/sjrir.v2i2.163.

Full text
Abstract:
Introduction: Metastatic bone disease (MBD) is a common complication of advanced cancer, causing significant morbidity and negatively impacting patients' quality of life. Targeted radionuclide therapy (TRT) has emerged as a promising treatment modality for MBD, offering targeted delivery of therapeutic radiation to bone metastases while minimizing damage to healthy tissues. Methods: A retrospective cohort study was conducted at leading oncology centers in Moscow, Russia, between 2018 and 2023. Patients with MBD who received TRT with either Strontium-89 or Samarium-153 were included. Data on pa
APA, Harvard, Vancouver, ISO, and other styles
33

Potluri, Hemanth K., Carolina A. Ferreira, Joseph Grudzinski, et al. "Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors." Journal for ImmunoTherapy of Cancer 10, no. 8 (2022): e005060. http://dx.doi.org/10.1136/jitc-2022-005060.

Full text
Abstract:
BackgroundSystemic radiation treatments that preferentially irradiate cancer cells over normal tissue, known as targeted radionuclide therapy (TRT), have shown significant potential for treating metastatic prostate cancer. Preclinical studies have demonstrated the ability of external beam radiation therapy (EBRT) to sensitize tumors to T cell checkpoint blockade. Combining TRT approaches with immunotherapy may be more feasible than combining with EBRT to treat widely metastatic disease, however the effects of TRT on the prostate tumor microenvironment alone and in combinfation with checkpoint
APA, Harvard, Vancouver, ISO, and other styles
34

Williams, L. "WE-E-214-03: Biology and Physiology of Targeted Radionuclide Therapy (TRT)." Medical Physics 38, no. 6Part33 (2011): 3822. http://dx.doi.org/10.1118/1.3613392.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Speer, T. W., P. Bernhardt, B. Bednarz, P. Harari, J. Saker, and B. Thomadsen. "Feasibility of the Systemic Cure of Cancer With Targeted Radionuclide Therapy (TRT)." International Journal of Radiation Oncology*Biology*Physics 84, no. 3 (2012): S709. http://dx.doi.org/10.1016/j.ijrobp.2012.07.1898.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Mdanda, Sipho, Lindokuhle M. Ngema, Amanda Mdlophane, Mike M. Sathekge, and Jan Rijn Zeevaart. "Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review." Pharmaceutics 15, no. 6 (2023): 1719. http://dx.doi.org/10.3390/pharmaceutics15061719.

Full text
Abstract:
The actinium-225 (225Ac) radioisotope exhibits highly attractive nuclear properties for application in radionuclide therapy. However, the 225Ac radionuclide presents multiple daughter nuclides in its decay chain, which can escape the targeted site, circulate in plasma, and cause toxicity in areas such as kidneys and renal tissues. Several ameliorative strategies have been devised to circumvent this issue, including nano-delivery. Alpha-emitting radionuclides and nanotechnology applications in nuclear medicine have culminated in major advancements that offer promising therapeutic possibilities
APA, Harvard, Vancouver, ISO, and other styles
37

Akil, Hussein, Mercedes Quintana, Jérémy H. Raymond, et al. "Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma." Cancers 13, no. 6 (2021): 1421. http://dx.doi.org/10.3390/cancers13061421.

Full text
Abstract:
Purpose: To assess the efficiency of targeted radionuclide therapy (TRT), alone or in combination with MEK inhibitors (MEKi), in melanomas harboring constitutive MAPK/ERK activation responsible for tumor radioresistance. Methods: For TRT, we used a melanin radiotracer ([131I]ICF01012) currently in phase 1 clinical trial (NCT03784625). TRT alone or combined with MEKi was evaluated in three-dimensional melanoma spheroid models of human BRAFV600E SK-MEL-3, murine NRASQ61K 1007, and WT B16F10 melanomas. TRT in vivo biodistribution, dosimetry, efficiency, and molecular mechanisms were studied using
APA, Harvard, Vancouver, ISO, and other styles
38

Müller, Cristina, Maria De Prado Leal, Marco D. Dominietto, et al. "Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute." Pharmaceutics 11, no. 9 (2019): 450. http://dx.doi.org/10.3390/pharmaceutics11090450.

Full text
Abstract:
Proton therapy (PT) is a treatment with high dose conformality that delivers a highly-focused radiation dose to solid tumors. Targeted radionuclide therapy (TRT), on the other hand, is a systemic radiation therapy, which makes use of intravenously-applied radioconjugates. In this project, it was aimed to perform an initial dose-searching study for the combination of these treatment modalities in a preclinical setting. Therapy studies were performed with xenograft mouse models of folate receptor (FR)-positive KB and prostate-specific membrane antigen (PSMA)-positive PC-3 PIP tumors, respectivel
APA, Harvard, Vancouver, ISO, and other styles
39

de Roode, Kim E., Lieke Joosten, and Martin Behe. "Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands." Pharmaceuticals 17, no. 2 (2024): 256. http://dx.doi.org/10.3390/ph17020256.

Full text
Abstract:
Targeted radionuclide therapy (TRT) is an emerging field and has the potential to become a major pillar in effective cancer treatment. Several pharmaceuticals are already in routine use for treating cancer, and there is still a high potential for new compounds for this application. But, a major issue for many radiolabeled low-to-moderate-molecular-weight molecules is their clearance via the kidneys and their subsequent reuptake. High renal accumulation of radioactive compounds may lead to nephrotoxicity, and therefore, the kidneys are often the dose-limiting organs in TRT with these radioligan
APA, Harvard, Vancouver, ISO, and other styles
40

Sun, M., C. Thomas, F. Orlando, et al. "1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)." Annals of Oncology 33 (September 2022): S1179. http://dx.doi.org/10.1016/j.annonc.2022.07.1522.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Cortiana, Viviana, Jade Gambill, Harshal Chorya, et al. "PSMA-Targeted Therapy: Advancements in Detection and Treatment Modalities with Dr. Scott T. Tagawa." Cancers 16, no. 10 (2024): 1833. http://dx.doi.org/10.3390/cancers16101833.

Full text
Abstract:
Prostate cancer is one of the most challenging malignancies due to its high incidence and prevalence, as it is the most frequently diagnosed non-skin cancer in men. The timely identification of prostate cancer and its metastasis is paramount for ensuring favorable outcomes for patients. Prostate-specific membrane antigen (PSMA) emerges as a promising biomarker for its detection, due to its specificity. This makes it an ideal target for the early identification of a metastatic phenotype. Situated on the membrane of tumor cells, PSMA facilitates the attachment of PSMA-targeting particles, enabli
APA, Harvard, Vancouver, ISO, and other styles
42

Sodji, Quaovi H., Matthew H. Forsberg, Dan Cappabianca, et al. "Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions." Cancers 16, no. 1 (2023): 191. http://dx.doi.org/10.3390/cancers16010191.

Full text
Abstract:
Background and purpose. Chimeric antigen receptor (CAR) T cells have been relatively ineffective against solid tumors. Low-dose radiation which can be delivered to multiple sites of metastases by targeted radionuclide therapy (TRT) can elicit immunostimulatory effects. However, TRT has never been combined with CAR T cells against solid tumors in a clinical setting. This study investigated the effects of radiation delivered by Lutetium-177 (177Lu) and Actinium-225 (225Ac) on the viability and effector function of CAR T cells in vitro to evaluate the feasibility of such therapeutic combinations.
APA, Harvard, Vancouver, ISO, and other styles
43

Li, Mengshi, Dijie Liu, Dongyoul Lee, et al. "Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma." Cancers 13, no. 15 (2021): 3676. http://dx.doi.org/10.3390/cancers13153676.

Full text
Abstract:
Radiotherapy can facilitate the immune recognition of immunologically “cold” tumors and enhance the efficacy of anti-PD-1 and anti-CTLA-4 immune checkpoint inhibitors (ICIs) in melanoma. Systemic administration of receptor-targeted radionuclide therapy has the potential to selectively deliver radionuclides to multiple tumors throughout the body in metastatic settings. By triggering immunologic cell death and increasing the immune susceptibility of surviving tumor cells in these locations, targeted radionuclide therapies may overcome resistance to ICIs and render immunologically “cold” tumors t
APA, Harvard, Vancouver, ISO, and other styles
44

Sun, Michael, Charlene Thomas, Benedict Ho, et al. "Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT)." Journal of Clinical Oncology 39, no. 15_suppl (2021): 5055. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.5055.

Full text
Abstract:
5055 Background: PSMA-TRT is a promising investigational treatment for patients with mCRPC. Expected short-term toxicities associated with PSMA-TRT include dose-dependent myelosuppression and xerostomia. However, there is a lack of information regarding long-term effects of PSMA-TRT on marrow, renal, and liver function. Additionally, potential organ dose limits for radiation are derived from studies of external beam radiation, which may not be applicable to TRT. Methods: Men treated on prospective clinical trials of PSMA-TRT, from 2003 through 2020 with at least six months of follow-up were in
APA, Harvard, Vancouver, ISO, and other styles
45

Thomas, Joseph Earl, Jones T. Nauseef, Michael Philip Sun, et al. "Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center." Journal of Clinical Oncology 41, no. 6_suppl (2023): 36. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.36.

Full text
Abstract:
36 Background: At Weill Cornell Medicine (WCM), we have had a research program utilizing anti-PSMA mAb J591 since the year 2000. With the addition of PSMA ligand-based therapies in 2017, we have enrolled around 300 patients on investigational PSMA-TRT clinical trials. Since the approval of 177Lu-PSMA-617 (Pluvicto; Lu-177 vipivotide tetraxetan), we began standard-of-care (SOC) treatment, co-enrolling willing patients into a research registry. Recognizing the low numbers of AA patients enrolled on therapeutic clinical trials in the U.S., we made a concerted effort to increase the number of AA p
APA, Harvard, Vancouver, ISO, and other styles
46

Magee, Kara, Ian R. Marsh, Michelle M. Turek, et al. "Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting." PLOS ONE 16, no. 8 (2021): e0255798. http://dx.doi.org/10.1371/journal.pone.0255798.

Full text
Abstract:
Rationale Murine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present studies on the safety and feasibility of this approach in a relevant translational companion dog model (n = 17 dogs) with advanced cancer. Methods The three component of the combination immuno-radiotherapy approach were employed either separately or in combination in companion dogs with advanced stage cancer. In situ vaccination was achieved through the administra
APA, Harvard, Vancouver, ISO, and other styles
47

Everix, Liesbeth, Shankari Nair, Cathryn H. S. Driver, et al. "Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma." Cancers 14, no. 7 (2022): 1821. http://dx.doi.org/10.3390/cancers14071821.

Full text
Abstract:
Despite numerous innovative treatment strategies, the treatment of glioblastoma (GB) remains challenging. With the current state-of-the-art therapy, most GB patients succumb after about a year. In the evolution of personalized medicine, targeted radionuclide therapy (TRT) is gaining momentum, for example, to stratify patients based on specific biomarkers. One of these biomarkers is deficiencies in DNA damage repair (DDR), which give rise to genomic instability and cancer initiation. However, these deficiencies also provide targets to specifically kill cancer cells following the synthetic letha
APA, Harvard, Vancouver, ISO, and other styles
48

Métivier, Cassandra, Patricia Le Saëc, Joëlle Gaschet, et al. "Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma." Pharmaceutics 15, no. 7 (2023): 1817. http://dx.doi.org/10.3390/pharmaceutics15071817.

Full text
Abstract:
Although the concept of theranostics is neither new nor exclusive to nuclear medicine, it is a particularly promising approach for the future of nuclear oncology. This approach is based on the use of molecules targeting specific biomarkers in the tumour or its microenvironment, associated with optimal radionuclides which, depending on their emission properties, allow the combination of diagnosis by molecular imaging and targeted radionuclide therapy (TRT). Copper-64 has suitable decay properties (both β+ and β- decays) for PET imaging and potentially for TRT, making it both an imaging and ther
APA, Harvard, Vancouver, ISO, and other styles
49

Muralidhar, Anusha, Reinier Hernandez, Zachary S. Morris, et al. "Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using90Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors." Journal for ImmunoTherapy of Cancer 12, no. 4 (2024): e008760. http://dx.doi.org/10.1136/jitc-2023-008760.

Full text
Abstract:
RationaleAndrogen deprivation therapy (ADT) is pivotal in treating recurrent prostate cancer and is often combined with external beam radiation therapy (EBRT) for localized disease. However, for metastatic castration-resistant prostate cancer, EBRT is typically only used in the palliative setting, because of the inability to radiate all sites of disease. Systemic radiation treatments that preferentially irradiate cancer cells, known as radiopharmaceutical therapy or targeted radionuclide therapy (TRT), have demonstrable benefits for treating metastatic prostate cancer. Here, we explored the us
APA, Harvard, Vancouver, ISO, and other styles
50

Vlachostergios, Panagiotis J., Muhammad Junaid Niaz, Seyed Ali Mosallaie, et al. "Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT)." Journal of Clinical Oncology 37, no. 15_suppl (2019): 5013. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5013.

Full text
Abstract:
5013 Background: Prostate surface membrane antigen (PSMA) is usually overexpressed in PC and is enriched in castration-resistant tumors. PSMA-TRT is of increasing interest to the field. Many in the field of theranostics have assumed that PSMA uptake on imaging is a pre-requisite for response. We have conducted a number of trials which have incorporated PSMA imaging, but have not selected patients for treatment based upon imaging results and performed an analysis examining the relationship between imaging and response. Methods: Men with mCRPC had either planar radiolabeled J591 imaging (111In-J
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography